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CRISPR technology and its application in cancer
―Describe the CRISPR system in prokaryotes.
―Specify the adaptation for gene editing.
―Analyze application of CRISPR in cancer.
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CRISPR technology for gene editing
1. Guide RNA 
design
-Determine the locus to be mutated.
-Using bioinformatic programs analyze:
➢ PAM sites 
➢ Off-targets
-Choose 20 nucleotides long sequence.
*sgRNA: single-chain chimeric guide RNA
(crRNA+tracrRNA)
2. Generation 
of gRNA 
(guide RNA) 
and Cas9
a) Two DNA plasmids.
-Appropriate promoters
-Cas9: codon-optimized
b) Two mRNAs.
-Cas9: 5’ cap and 3 polyA
+ codon-optimized.
c)    RNA/protein (RNP) complex.
Novel Cas proteins
How to stablish a CRISPR/Cas approach?
The most commonly used Cas9 in genome editing is the one of S. pyogenes (SpCas9) that recognizes 5’-NGG-3’ PAM. 
Figure 1. CRISPR/Cas9 immunity is based in three major phases: adaptation, expression and interference. In the
adaptive phase, the protospacer sequence near a specific protospacer adjacent motif (PAM) is integrated by Cas1 and Cas2 into
the CRIPSR locus. In the expression and interference phase, precursor CRISPR RNA (pre-crRNA) is synthesized and processed by
RNase III into crRNAs, which forms a complex with tracrRNA and Cas9. When this complex pairs with exogenous DNA by
recognition of the PAM by Cas9 and complementarity between crRNA and the protospacer, Cas9 cuts the foreign DNA.
Type II CRISPR/Cas9 immune system
3. 
Interference 
phase
-gRNA and Cas9 form a complex.
-Recognition and binding to the target 
sequence.
-Target DNA cleavage by Cas9. 
Application of CRISPR in CAR T cell therapy
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Figure 2. Workflow of a Phase I clinical trial carried out by the Chinese
PLA General Hospital (NCT03747965). Patient T cells are engineered to
express CARs whose antigen binding domain recognizes mesothelin antigen and
endogenous PD-1 expression is knocked-out with CRISPR.
Why is programmed cell death 
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Figure 3. Inhibition of T cell
antitumor response. Activated CD8+ T
cells secrete interferon  (INF ) that
upregulates programmed cell death
ligand-1 (PD-L1) expression in tumor cells.
Binding of PD-L1 to PD-1 inhibits CD8+ T
cell cytotoxic activity.
Chimeric Antigen Receptor (CAR)
1. CRISPR technology is faster, simpler
and cheaper comparing with the
design of Zinc Fingers or Transcription
activator-like effector nucleases
(TALENs).
2. Improvements in CRISPR efficiency
and off-targets effects due to Cas9
variants.
3. PD-1 knockout in CAR-T cell therapy
decreases T cell exhaustion and
increases their persistence.
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Figure 4. Receptor structure.
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Cas9n (nickase enzyme)
Single-stranded cut (nick).
dCas9 (nuclease deficient Cas9)
Target modifications of loci.
Cas9-HF1 (high fidelity Cas9)
No off-targets.
SaCas9
Encoded by a 3,2Kb sequence.
Cas12a
Staggered DNA breaks.
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